Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

CAPS Rating: 3 out of 5

A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases

Results 1 - 16 of 16

Recs

0
Member Avatar genedom (98.84) Submitted: 3/11/2014 11:43:12 PM : Underperform Start Price: $3.15 ACHN Score: +8.43

No future

Recs

1
Member Avatar HarHarMahadev (< 20) Submitted: 2/4/2014 12:02:15 PM : Outperform Start Price: $3.33 ACHN Score: -19.67

Lot of Institutional buying recently..

Recs

0
Member Avatar Haugurafpeningum (88.85) Submitted: 1/25/2014 4:14:28 PM : Outperform Start Price: $3.66 ACHN Score: -25.39

porte3 bottom of a rising trendchannel

Recs

4
Member Avatar zzlangerhans (99.74) Submitted: 10/7/2013 4:19:14 AM : Outperform Start Price: $2.82 ACHN Score: -8.49

Achillion suffered a rather surprising meltdown after the close last Friday, having dropped a double whammy on their shareholders: the FDA declined to lift a partial clinical hold on soraprevir, and the RVR interim data from the 007 trial of soraprevir/ACH-3102 all oral regimen for hep C was a disappointing 79% overall. Unsurprisingly, the share price declined more than 50%. Of course, in these types of situations there's usually a contingent of resolute defenders of the stock, ready to minimize the negative implications of the catalysts.

The odd thing about this particular situation was the absence of defenders of the company, as bulls threw in the towel across the spectrum. Notable were white flags from The Street, Seeking Alpha, and insider QVT who sold almost all of their recent 3M share bet on the stock. Now, that should be a warning to anyone looking to trade the stock - those with the greatest motivation to press for a rebound decided to fold instead. Perhaps Achillion has fallen down a rabbit hole from which there's no escape. On the other hand, Achillion's share price may have reached an equilibrium quickly due to the vigorous selling. There's certainly a potential opportunity here.

What does Achillion have left? There's no guarantee of any significant future commercial revenues in the hep C space. The prevailing point-of-view is that the hep C field has become a horse race where the first to market with all-oral regimens will dominate for the foreseeable future. That may be the case, but it's also undeniable that Achillion has relatively advanced candidates with extensive safety and efficacy data through phase II. Soraprevir is only under a partial clinical hold related to coadministration with HIV meds, and the weakness of the 007 trial could be an aberration of the particular combination of drugs that was chosen. The company also has several other hep C drugs in various classes in early clinical and preclinical development. With 134M in cash as of the end of Q2 and a quarterly burn of 10-15M, the company has some time to retrench otself and attempt to generate some new midstage trial data before the situation becomes dire.

The zzporte collaboration made an inital foray into the stock with a somewhat premature buy of 800 shares at 3.53. Fortunately, that's not a big position for us since the stock has dropped as much as 25% from there. At the current level the company has an enterprise value of 150M, which I think is an interesting level and possibly worthy of an increase in the size of the position. I think the price action in the early part of this week will help solidify our thinking about the short term direction of the stock.

Recs

0
Member Avatar whoodatstockhot (85.97) Submitted: 9/30/2013 12:50:22 PM : Outperform Start Price: $2.94 ACHN Score: -12.77

One of the best buying opportunites I've seen all year. Stonrg pipeline of hepatitis C medicines in its portfolio.

Recs

0
Member Avatar fatmoneyrz (95.68) Submitted: 9/30/2013 9:47:42 AM : Outperform Start Price: $3.50 ACHN Score: -28.91

This is a best in breed, but volatile one, which should head right back up. Take advantage of the sell offs

Recs

0
Member Avatar TerryHoodSr (53.44) Submitted: 7/31/2013 3:46:45 PM : Outperform Start Price: $6.37 ACHN Score: -65.31

potential

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:10:16 PM : Underperform Start Price: $7.18 ACHN Score: +70.10

Short. Biopharma. Big insider selling. 6000x P/S . Last 3 years cash flow from selling stock: 44M, 61M, 72M. (Much more than investing activities).

Recs

0
Member Avatar Fishbolb (52.95) Submitted: 10/16/2012 6:42:19 PM : Underperform Start Price: $10.78 ACHN Score: +101.97

Late to the Hep C game.

Recs

1
Member Avatar getrichslowfool (< 20) Submitted: 1/13/2012 3:21:38 PM : Outperform Start Price: $12.32 ACHN Score: -122.22

Yeah it's run up a bunch recently, but I think IDIX will get bought out and this will run up more with it. Time will tell

Recs

0
Member Avatar jamescraigjones (< 20) Submitted: 10/19/2011 10:43:10 AM : Outperform Start Price: $6.22 ACHN Score: -106.11

It is clear to see that the Hep C market will be exploding in the next year to 3 years as developers continue to improve on the technology and pipelines. Regardless of how the sector or the overall market is performing, you cant ignore the kind of money that this market will tap into.

Recs

0
Member Avatar EclecticRecluse (78.65) Submitted: 5/25/2011 10:01:35 AM : Underperform Start Price: $5.87 ACHN Score: +92.52

Low Sales and Return on Equity

Recs

0
Member Avatar THEMATHISNEAR (< 20) Submitted: 2/17/2011 10:24:28 AM : Underperform Start Price: $5.99 ACHN Score: +102.69

Shorting a bunch of biotechs that have run up for no reason. Yes, I expect one to pop, and don't know which one, but I expect that most will fail outright, and the group as a whole will fail to match the S&P.

Recs

0
Member Avatar poorbastard2011 (< 20) Submitted: 1/14/2011 7:04:28 AM : Outperform Start Price: $5.04 ACHN Score: -88.79

Long Term Bullish Breakout
Short Term Upward Sloping Trading Channel
Short Term Bullish Breakout

Recs

0
Member Avatar NetscribePhrmtcl (97.74) Submitted: 3/20/2007 8:42:53 AM : Underperform Start Price: $7.06 ACHN Score: +94.95

Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, the company concentrates on the development of antivirals and antibacterials. It is targeting the antiviral development efforts on treatments for HIV infection and chronic hepatitis C, and is directing its antibacterial development efforts toward treatments for serious hospital-based bacterial infections.

Its two lead drug candidates are Elvucitabine, which is in the Phase II clinical trials in HIV-infected patients, and ACH-806, which the company is evaluating in collaboration with Gilead Sciences in a Phase I clinical trial for the treatment of chronic hepatitis C. The company is also evaluating its third drug candidate, ACH-702, in late-stage, pre-clinical studies for the treatment of serious hospital-based bacterial infections.

Revenues witnessed a sharp 91% decline for the quarter ended September 2006. The decrease in 2006 is the result of a reduction in milestone payments under collaboration with Gilead Sciences. Net loss applicable to common shareholders increased 71%, reflecting a sharp increase in R&D expenses and administrative costs. The company has incurred losses of $100 million from inception to September 2006 and had an accumulated deficit of $113.6 million through September 30, 2006.

Achillion appears to be a weak investment proposition based on the delay in the expected development timeline for the HIV & HCV program. The launch of a replicase inhibitor for HCV is expected to be in 2011, rather than 2010, which would hamper the company’s near term earning prospects.

Recs

0
Member Avatar turingmouse (40.97) Submitted: 2/12/2007 2:05:24 AM : Outperform Start Price: $9.22 ACHN Score: -106.94

took to much of a beating on hep-c trial news. should outperform.

Results 1 - 16 of 16

Featured Broker Partners


Advertisement